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ABSTRACT
The increased frequency and dissemination of enterobacteria resistant to various antimicrobials is currently worldwide concern. In 
January 2010, a 94-year-old patient with chronic lymphocytic leukemia was admitted to the University Hospital. This patient died 
21 days after hospitalization due to the clinical worsening. Klebsiella pneumoniae producing of extended-spectrum  β-lactamases 
(ESBLs) was isolated of urine culture. This bacterium demonstrated resistance to ceftazidime, ciprofloxacin, levofloxacin, 
ertapenem and imipenem. Susceptibility to cefoxitin, cefepime, meropenem, colistin and tigecycline. This study reports the first 
case of infection by Klebsiella pneumoniae carrying the bla
kpc
 gene in the State of Mato Grosso do Sul, Brazil.
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The emergence of β-lactamases producing enterobacteria has 
been considered one of the major challenges faced by hospitals 
in recent decades. Recent reports have shown an increasing 
prevalence of these enterobacteria, especially Klebsiella 
pneumoniae strains resistant to carpabenens, antibiotics 
indicated for the treatment of patients who are infected with 
bacteria producing extended-spectrum β-lactamases (ESBLs)1.
The Klebsiella pneumoniae carbapenemase (KPC-KPN) was 
first described in 1996 in North Carolina, USA2. In Brazil, the 
first reports of KPC-KPN infection among Northeastern patients 
were described in 20063. However, there is also evidence that 
the carpabenem-resistant genotype was described in 2005 in São 
Paulo4. Since then, this microorganism has been disseminate to 
several hospitals in different Brazilian states5-7.
Case RepORT
In January 2010, a 94-year-old female patient who had been 
diagnosed with chronic lymphocytic leukemia was hospitalized 
in a teaching hospital with 256 beds in Campo Grande, State 
of Mato Grosso do Sul, Midwest Brazil. This patient presented 
with the following symptoms: a cough with sputum production, 
hoarseness, sibilance, dyspnea and a fever of 39ºC. The patients’ 
blood pressure and glycemia were normal. Antibiotic therapy, 
consisting of ceftriaxone 1g twice daily, and clindamycin 
600mg three times a day for 10 days. During the period of 
hospitalization, she developed a urinary tract infection, and 
there was a concomitant worsening of her laboratorial results 
and clinical condition. The antimicrobial therapy was first 
switched to ciprofloxacin and piperacilin/tazobactam and was 
subsequently included vancomycin and fluconazole (yeast in 
the urine) due to the patient’s persistent clinical worsening. 
However, the patient died 21 days after hospitalization.
The patient had used a central venous catheter for 17 days, 
and a three-way catheter was used for vesical catheterization 
over the course of 19 days, with three removals. The urine 
samples collected at 12 and 15 days post-hospitalization 
resulted in positive cultures containing greater than 105 
UFC/mL (colony forming units/mL) Klebsiella pneumoniae 
was isolated, and the result of the Modified Hodge Test was 
positive. Moreover, the results produced by the VITEK 2 
automated system (bioMérieux, Marcy l'Etoile, France) revealed 
that the patothogen was producing ESBLs and demonstrated 
resistance to ceftazidime, the fluoroquinolones ciprofloxacin and 
levofloxacin, and the carbapenemic ertapenem and imipenem 
and susceptibility to cefoxitin, cefepime, meropenem, colistin 
and tigecycline (Table 1).
The first positive urine culture sample was sent to the 
Laboratório Especial de Microbiologia Clínica da Universidade 
Federal de São Paulo, where bla
kpc-2
 gene was detected by 
polymerase chain reaction analysis followed by deoxyribonucleic 
acid (DNA) sequencing3. The study was approved by the Research 
Ethics Committee of Universidade Federal de Mato Grosso do 
Sul (UFMS).
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DIsCUssION
TABLE 1 - Antimicrobial susceptibility profile of the Klebsiella pneumoniae strain 
isolated from the patient’s urine culture.
 Minimum inhibitory  
Antimicrobials concentration (µg/mL) Interpretation*
Cefoxitin 8 susceptible
Ceftazidime ≥ 64 resistant
Cefepime 8 susceptible
Meropenem 1 susceptible
Ertapenem  4 resistant
Ciprofloxacin 4 resistant
Levofloxacin ≥ 8 resistant
*Clinical and Laboratory Standards Institute, 2011.
The clonal dissemination of KPC-KPN strains across 
hospitals throughout the world has been documented7,8. Since 
the first description in 2009, which was made by Monteiro et 
al.3, sporadic cases and outbreaks have been reported in Brazil5,9. 
The case presented here represents the first report of infection 
with Klebsiella pneumoniaebcarrying the bla
kpc
 gene in the State 
of Mato Grosso do Sul, Midwest Brazil.
Between 2009 and 2010, an increased number of notifications 
were made to the Agência Nacional de Vigilância Sanitária 
(ANVISA) concerning outbreaks in different regions of the 
country, which generated a national response. Faced with 
this situation, ANVISA published a technical standard in an 
attempt to control the dissemination of these multidrug-resistant 
microrganisms10. The dissemination of resistant strains mainly 
results from the lack or failure of proper therapeutic treatments, 
and the results of such dissemination can be catastrophic if 
effective control measures are not undertaken.
Infections caused by multidrug-resistant enterobacteriaceae 
tend to be more frequent among elderly patients with impaired 
immune systems. This is especially true for those who have 
other comorbidities5, such as the patient described here, who 
was elderly and also had chronic lymphocytic leukemia. 
Moreover, these types of infections are usually associated with 
high lethality5,8. 
According to the literature, invasive procedures, such 
as the use of central venous catheters or urinary catheters, 
are significant routes of infection resulting from healthcare 
interventions11. In the cases reported by Beirão et al.5, all of 
the patients diagnosed with KPC-KPN infections, which had 
been isolated from the urine, had been given urinary catheters.
It is important to note that the minimum inhibitory 
concentration (CIM) for meropenem from the sample of 
KPC-KPN was characterized as susceptible according to the 
Clinical and Laboratory Standards Institute (CLSI) criteria12, which 
indicates a risk of therapeutic failure for cases of infection treated 
with this antimicrobial.
Health surveillance studies and molecular analyses aimed 
at identifying antibiotic resistance genes are required for 
optimal detection of the emergence and occurrence of future 
KPC-KPN outbreaks. Moreover, such analyses and studies may 
also identify the likelihood of further dissemination of these 
genes in Brazil.
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